Symbols

PALI

Palisade Bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PALI

Palisade Bio, Inc.

A clinical-stage biopharmaceutical company focused on developing oral therapies for serious diseases associated with disruption of the mucosal barrier that protects the gastrointestinal tract

Industry

Biological Technology

Established Date

Listing Date

07/13/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.palisadebio.com

Security Type

Common stock

Office address

4600 South Syracuse Street, Suite 900, Denver, Colorado 80237

Business

Introduction

Palisade Bio, Inc., originally incorporated in Delaware in 2001 under the name Neuralstem, Inc., changed its name and completed the merger in 2021. The Company is a clinical-stage biopharmaceutical company focused on the development of next-generation once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases, and its lead drug candidate, PALI-2108, is being developed for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

Company Financials

EPS

PALI has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.55, beating expectations. The chart below visualizes how PALI has performed over recent quarters, highlighting trends in earnings surprises.